Introduction to Infectious Disease
Infectious disease research is a dynamic field focused on combating microscopic threats to human health. These diseases, caused by bacteria, viruses, fungi, and parasites, demand a comprehensive understanding of their biology, transmission modes, and host responses for effective outbreak management.Â
Infectious diseases research, centered on pathogenic microorganisms, dives deep into the complexities between pathogens and hosts, spanning epidemiology, immunology, and molecular biology. Researchers aim to decipher host-pathogen dynamics and formulate interventions with demonstrable efficacy. Scientists study the genetic architecture, replication strategies, and virulence factors that empower microorganisms to thrive within hosts, thus advancing the development of vaccines, antiviral drugs, and antimicrobial strategies.Â
The impact of infectious diseases research is profound, shaping public health paradigms, clinical methodologies, and global disease control efforts. Breakthroughs in this field have yielded life-saving vaccines, potent antibiotics, and innovative diagnostic tools, actively combatting emerging threats and contributing to a healthier, safer world.Â
With a catalog boasting over 15,000 protein targets, trial sizes for exploring emerging projects, and advanced validation methods, Aviva is dedicated to supporting researchers as they pave the way for new discoveries and breakthroughs in Infectious Disease research.Â
Featured Products
Sample Type: IL-6 ELISA Standard Curve IL-6 ELISA Kit (Human) (OKBB00189) - Standard Curve. Colorimetric, OD 450 nm. ELISA Kit Range: 4.69 pg/ml - 300 pg/ml. High specificity for detection of Natural and recombinant human IL-6, click here |
Sample Type: MDCK uninfected and infected w/ Influenza B virus cell lysates Influenza B Virus NucleoProtein Antibody (OAGA08447) - Influenza B Virus NP antibody [GT382] detects Influenza B Virus NP protein by Western blot analysis. A. 10 ug MDCK whole cell lysate/extract B. 10 ug whole cell lysate/extract of Influenza B virus (Taiwan 70555) infected MDCK cells. 7.5 % SDS-PAGE Influenza B Virus NP antibody [GT382] dilution: 1:5000, click here |
Sample Type: Immobilized SARS-CoV-2-S1-RBD SARS-CoV-2 Spike RBD Nanobody Recombinant Antibody [A1] (OACA12524) - Activity Assay- ELISA. The Binding Activity of SARS-CoV-2 Spike RBD Nanobody with SARS-CoV-2-S1-RBD Activity: Measured by its binding ability in a functional ELISA. Immobilized SARS-CoV-2-S1-RBD at 2 μg/ml can bind SARS-CoV-2 Spike RBD Nanobody, the EC50 is 0.8674 ng/ml. click here |
Â